Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice
| Autor: | Florence Thibaut, Jean-Marie Vaugeois, Jean Costentin, J.-J. Bonnet |
|---|---|
| Přispěvatelé: | Unité de neuropsychopharmacologie expérimentale (ESA 6036), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS) |
| Rok vydání: | 1996 |
| Předmět: |
medicine.medical_specialty
Dextroamphetamine Dopamine Dopamine Agents Tritium Levodopa Mice 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 4-Butyrolactone Cocaine Dopamine Uptake Inhibitors Dopamine Uptake Complex Cerebellum Internal medicine Desipramine medicine Animals GABA Modulators Neurotransmitter 030304 developmental biology Dopamine transporter Analysis of Variance 0303 health sciences Mazindol biology General Neuroscience Dopaminergic 3. Good health Neostriatum Endocrinology nervous system chemistry Injections Intravenous biology.protein Catecholamine [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology 030217 neurology & neurosurgery Protein Binding medicine.drug |
| Zdroj: | Neuroscience Letters Neuroscience Letters, Elsevier, 1996, 205 (3), pp.145-8. ⟨10.1016/0304-3940(96)12399-5⟩ |
| ISSN: | 0304-3940 |
| DOI: | 10.1016/0304-3940(96)12399-5 |
| Popis: | We have considered the in vivo striatal binding of two ligands of the neuronal dopamine uptake complex: [ 3 H]cocaine and [ 3 H]mazindol. The [ 3 H]cocaine tracer dose labelled the dopamine uptake complex in striatum but not the noradrenaline complex in cerebellum. On the contrary, the [ 3 H]mazindol tracer dose induced a marked labelling of the noradrenaline uptake complex in cerebellum; its prevention by desipramine (5 mg/kg) increased simultaneously the cerebral bioavailability and thereby the striatal labelling of the dopamine transporter. In mice submitted to treatments modifying dopaminergic transmission either to decrease it (gammabutyrolactone, 750 mg/kg, i.p.) or to increase it ( l -DOPA, 200 mg/kg, i.p., dexamphetamine, 4 mg/kg, s.c., or their combination), only dexamphetamine pretreatment significantly reduced [ 3 H]cocaine and [3H]mazindol binding. Thus it appears that the level of dopamine transmission would not interfere with the in vivo quantification of striatal dopamine uptake sites assessed with either ligands. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect